Log in

NASDAQ:DOVADova Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$28.04
0.00 (0.00 %)
(As of 11/12/2019)
Add
Compare
Today's Range
$28.04
Now: $28.04
$28.04
50-Day Range
$28.04
MA: $28.04
$28.04
52-Week Range
$5.62
Now: $28.04
$28.54
Volume35,036 shs
Average Volume499,313 shs
Market Capitalization$807.55 million
P/E RatioN/A
Dividend YieldN/A
Beta2.74
Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.
Read More
Dova Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.05 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DOVA
CUSIPN/A
Phone919-748-5975

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.35 million
Book Value$2.71 per share

Profitability

Net Income$-72,280,000.00
Net Margins-544.09%

Miscellaneous

Employees115
Market Cap$807.55 million
Next Earnings DateN/A
OptionableOptionable

Receive DOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for DOVA and its competitors with MarketBeat's FREE daily newsletter.

Dova Pharmaceuticals (NASDAQ:DOVA) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Dova Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dova Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Dova Pharmaceuticals.

How were Dova Pharmaceuticals' earnings last quarter?

Dova Pharmaceuticals Inc (NASDAQ:DOVA) released its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.03. The company had revenue of $3.52 million for the quarter, compared to the consensus estimate of $5.63 million. Dova Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 544.09%. View Dova Pharmaceuticals' earnings history.

What price target have analysts set for DOVA?

5 brokerages have issued 12-month price targets for Dova Pharmaceuticals' shares. Their forecasts range from $27.50 to $30.00. On average, they expect Dova Pharmaceuticals' stock price to reach $28.70 in the next twelve months. This suggests a possible upside of 2.4% from the stock's current price. View analysts' price targets for Dova Pharmaceuticals.

Has Dova Pharmaceuticals been receiving favorable news coverage?

Headlines about DOVA stock have been trending negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dova Pharmaceuticals earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an effect on the stock's share price in the next few days. View the latest news about Dova Pharmaceuticals.

Who are some of Dova Pharmaceuticals' key competitors?

What other stocks do shareholders of Dova Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dova Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Global Blood Therapeutics (GBT), Sasol (SSL), Aldeyra Therapeutics (ALDX), TESARO (TSRO), TherapeuticsMD (TXMD), Allena Pharmaceuticals (ALNA), Fate Therapeutics (FATE), Heron Therapeutics (HRTX) and Immunomedics (IMMU).

Who are Dova Pharmaceuticals' key executives?

Dova Pharmaceuticals' management team includes the following people:
  • Dr. David S. Zaccardelli, Pres & CEO (Age 54)
  • Mr. Mark W. Hahn, CFO & Sec. (Age 56)
  • Mr. Kevin Laliberte, Sr. VP of Product Devel. (Age 41)
  • Mr. Jason Levine, VP of Marketing
  • Mr. Ilija Zlatar, Head of U.S. Sales

When did Dova Pharmaceuticals IPO?

(DOVA) raised $66 million in an initial public offering on Thursday, June 29th 2017. The company issued 4,100,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is Dova Pharmaceuticals' stock symbol?

Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."

What is Dova Pharmaceuticals' stock price today?

One share of DOVA stock can currently be purchased for approximately $28.04.

How big of a company is Dova Pharmaceuticals?

Dova Pharmaceuticals has a market capitalization of $807.55 million and generates $10.35 million in revenue each year. The company earns $-72,280,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Dova Pharmaceuticals employs 115 workers across the globe.

What is Dova Pharmaceuticals' official website?

The official website for Dova Pharmaceuticals is www.dova.com.

How can I contact Dova Pharmaceuticals?

Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.